États-Unis · Plateformes & données · MarketBeat

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Publié par MarketBeat · États-Unis il y a 2 h

LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride,…

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

À lire aussi

Dutch Bros vs. Kimberly-Clark: Which Is the Smarter Buy Today?

A leading Silicon Valley cheerleader just showed all the reasons to be worried about the AI bubble

Why is SK Hynix stock surging today?

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Popular crypto stock surges as Q3 earnings top estimates

Novartis Raises Guidance After Trial Setbacks Hit Profit

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Partager

À lire aussi

Dutch Bros vs. Kimberly-Clark: Which Is the Smarter Buy Today?

A leading Silicon Valley cheerleader just showed all the reasons to be worried about the AI bubble

Why is SK Hynix stock surging today?

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Popular crypto stock surges as Q3 earnings top estimates

Novartis Raises Guidance After Trial Setbacks Hit Profit